Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Aroa Biosurgery Ltd ( (AU:ARX) ) has shared an update.
Aroa Biosurgery reported preliminary unaudited FY26 results showing total revenue of about NZ$104 million on an actual basis, or NZ$101 million in constant currency, surpassing its guidance range and representing 21% growth on the prior year, driven mainly by a 52% constant-currency sales surge in its Myriad portfolio. Normalised EBITDA is expected at NZ$11–12 million (NZ$10–11 million constant currency), also ahead of guidance and supported by higher revenue, favourable foreign exchange and the deferral of some development project costs into FY27, leaving the company with positive net cash flow of NZ$5 million and a strengthened cash balance of NZ$27 million ahead of its full audited results release in late May.
The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.16 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.
More about Aroa Biosurgery Ltd
Aroa Biosurgery Limited is a New Zealand-based soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are built on a proprietary AROA ECM technology platform derived from ovine forestomach, with more than 7 million products used globally and a primary commercial focus on the U.S. market through a direct sales force and distribution partner TelaBio, Inc.
Average Trading Volume: 141,625
Technical Sentiment Signal: Sell
Current Market Cap: A$186.8M
For detailed information about ARX stock, go to TipRanks’ Stock Analysis page.